The highly glycosylated transmembrane
protein extracellular matrix metalloproteinase inducer (
EMMPRIN) is associated with several pathological conditions, including various types of
cancers. In different gynecological
malignancies, such as ovarian, cervical, and
endometrial cancers,
EMMPRIN plays significant roles in cell adhesion modulation,
tumor growth, invasion, angiogenesis, and
metastasis by inducing the production of various molecules, including
matrix metalloproteinases and
vascular endothelial growth factor. Because of its high level of expression,
EMMPRIN can possibly be used as a diagnostic marker of gynecological
cancers. Recent studies have showed that targeting
EMMPRIN, especially by RNA interference (RNAi) technology, has promising therapeutic potential in basic research on gynecological
cancer treatments, which make a platform for the future clinical success. This review study focused on the association of
EMMPRIN in gynecological
cancers in the perspectives of pathogenesis, diagnosis, and
therapeutics.